By Jeff Sistrunk (October 19, 2016, 6:00 PM EDT) -- An investor's suit accusing Theranos Inc. of misrepresenting its blood-testing technologies and a U.S. Securities and Exchange Commission probe of the startup may lead insurers to broaden exclusions in directors and officers policies to reflect privately held firms' growing exposure to securities law claims, experts say.
In an Oct. 11 complaint filed in Delaware Chancery Court, hedge fund Partners Investments LP is seeking to rescind its agreement to purchase Theranos stock based on alleged misstatements made by the medical testing firm and its principals.
The suit, coupled with the SEC's heightened scrutiny of Theranos and other privately held "unicorns" with valuations...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!